1005030-66-9

Usage

Uses

Used in Pharmaceutical Synthesis:
1,6-Naphthyridine-2-carboxylic acid ethyl ester is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Production:
In the agrochemical industry, 1,6-Naphthyridine-2-carboxylic acid ethyl ester is utilized as a precursor in the creation of compounds designed to protect crops and enhance agricultural productivity.
Used in Antimicrobial Research:
1,6-Naphthyridine-2-carboxylic acid ethyl ester is employed as a subject of study in antimicrobial research, given its potential to combat various microorganisms, which could lead to the development of new antimicrobial agents.
Used in Antitumor Drug Development:
1,6-Naphthyridine-2-carboxylic acid ethyl ester is also used in antitumor drug development due to its demonstrated potential biological activities against tumor cells, offering a pathway to novel cancer treatments.

Upstream product

• 541-41-3 chloroformic acid ethyl ester 
• 197507-59-8 1,6-naphthyridine-2-carboxylic acid 

Relevant academic research and scientific papers

LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS

The present invention relates to the use of a compound of formula (I): in which R1 represents a radionuclide, Ar represents an aromatic nucleus, m is an integer varying from 2 to 4, R2 and R3 represent, independently of one another, a hydrogen atom, a (C1

Evaluation of radiolabeled (Hetero)aromatic analogues of N-(2-diethylaminoethyl)-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma

Targeted radionuclide therapy using radioiodinated compounds with a specific affinity for melanoma tissue is a promising treatment for disseminated melanoma, but the candidate with the ideal kinetic profile remains to be discovered. Targeted radionuclide therapy concentrates the effects on tumor cells, thereby increasing the efficacy and decreasing the morbidity of radiotherapy. In this context, analogues of N-(2-diethylaminoethyl)-4- iodobenzamide (BZA) are of interest. Various (hetero)aromatic analogues 5 of BZA were synthesized and radioiodinated with 125I, and their biodistribution in melanoma-bearing mice was studied after i.v. administration. Most [125I]5-labeled compounds appeared to bind specifically and with moderate-to-high affinity to melanoma tumor. Two compounds, 5h and 5k, stood out with high specific and long-lasting uptake in the tumor, with a 7- and 16-fold higher value than BZA at 72 h, respectively, and kinetic profiles that makes them promising agents for internal targeted radionuclide therapy of melanoma.